Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Arvinas, Inc.NASDAQ: ARVN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $15M a year earlier. Trailing-twelve-month stock-based compensation was $18.8M. Over 3 fiscal years it compounded at -16.5% a year.

Context

  • Stock-based compensation amounted to 16.8% of revenue in FY2025, down 16.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $4.7M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$44M-50.1% YoY
LTMMar 2026
$18.8M-77.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-50.1%——
3-year CAGR-16.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
44M USD
Year-over-year change
-50.1%
4-year CAGR
-6.3%

Stock-Based Compensation vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 stock-based compensation of $18.8M is the 4th largest of the 6 companies compared; the peer median is $19.52M.
  • Its year-over-year change of -77.8% is the lowest of 6, against a peer median of +8.7%.
  • Stock-based compensation amounts to 21.0% of revenue for ARVN, versus a peer median of 45.4%.
ARVN Competitors Peer median
Stock-Based Compensation for ARVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$65.2M +11.7%+19.1%62.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M +8.7%+10.5%5.8%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$19.52M +5.2%+17.4%45.4%
ARVNArvinas, Inc.LTM Mar 2026$18.8M -77.8%-16.5%21.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M -43.8%-14.0%46.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
Peer median (excluding ARVN) $19.52M+8.7%+13.9%45.4%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
Deferred Income Tax00000
Stock-Based Compensation57.1M75.5M71.6M88.2M44M
Change in Working Capital678.3M(82.6M)(44.4M)(140.6M)(233.7M)
Accounts Receivables(30.2M)14M800K(5.7M)7.3M
Inventory00000
Accounts Payables27.9M20.2M17.3M(21.2M)(1.7M)
Other Working Capital680.6M(116.8M)(62.5M)(113.7M)(239.3M)
Other Non-Cash Items9M7.9M(14.4M)(14.6M)(8.5M)
Operating Cash Flow559.4M(273.5M)(347.8M)(259.3M)(273.8M)
Capital Expenditures(4.7M)(6.8M)(2.9M)(1.8M)(1.9M)
Acquisitions (Net)0400K0100K0
Purchases of Investments(1.74B)(886.4M)(956.3M)(652.1M)(354.2M)
Sales of Investments435.7M1.14B1.16B688.5M763.7M
Other Investing Activities0(400K)000
Investing Cash Flow(1.31B)242.8M203.5M34.7M407.6M
Debt Repayment000(400K)(200K)
Common Stock Issued264.6M4.7M387.2M8.3M700K
Common Stock Repurchased0000(91.9M)
Dividends Paid00000
Other Financing Activities14M0000
Financing Cash Flow278.6M4.7M374.7M7.9M(91.4M)
Effect of Forex Changes00000
Net Change in Cash(475.6M)(26M)230.4M(216.7M)42.4M
Free Cash Flow554.7M(280.3M)(350.7M)(261.1M)(275.7M)

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.